MannKind Corporation
Use of ultrarapid acting insulin

Last updated:

Abstract:

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

Status:
Grant
Type:

Utility

Filling date:

29 Jun 2018

Issue date:

15 Sep 2020